TaiwanJ Pharmaceuticals Co., Ltd. (6549.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$6.70 (+0.00%) as of
Key statistics
- Market cap
- 536.82M
- EPS (TTM)
- -0.22
- Dividend yield
- 0.00%
- 52-week range
- 6.21 – 9.80
- Beta
- -1.12
- Profit margin
- 0.00%
- Volume
- 51.00
About TaiwanJ Pharmaceuticals Co., Ltd.
TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis. The company was incorporated in 2011 and is based in Zhubei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Zhubei, Taiwan
- Employees
- 13
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.